MANNKIND CORP

MNKD ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $5.9M $27.6M $-11.9M $-87.4M $-80.9M $-57.2M $-51.9M $-87.0M
Depreciation & Amortization $12.3M $7.4M $4.5M $3.3M $2.0M $2.1M $972.0K $2.9M
Depreciation $8.1M $7.3M $4.5M $3.3M $2.0M $1.8M $1.6M $1.7M
Amortization $4.0M
Stock-Based Compensation $24.2M $21.4M $17.6M $13.4M $12.2M $6.5M $6.2M $6.9M
Net Cash from Operating Activities $18.3M $42.5M $34.1M $-80.7M $-61.7M $-28.1M $-88.5M $-37.7M
Investing Activities
Capital Expenditures $4.6M $9.7M $42.4M $7.6M $11.5M $801.0K $2.6M $354.0K
Business Acquisitions $347.7M $15.3M
Net Cash from Investing Activities $-304.8M $-96.6M $-2.0M $4.9M $-151.5M $15.2M $-22.8M $-234.0K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $315.1M $-137.3M $136.6M $21.4M $270.3M $49.9M $69.9M $61.3M
Net Change in Cash $28.6M $-191.4M $168.7M $-54.4M $57.0M $36.9M $-41.5M $23.3M
Free Cash Flow $13.7M $32.8M $-8.3M $-88.3M $-73.2M $-28.9M $-91.0M $-38.1M
← Newer Page 1 of 5 Older →